Physicians voice concern over ibrutinib flat pricing

Brian T. Hill, MD, PhD, director of the Lymphoid Malignancies Program at the Cleveland Clinic’s Taussig Cancer Institute, prescribes ibrutinib fairly regularly. He was not involved in the drafting of the letter but said he supports the intent.

“This is a significant inconvenience and a potential problem for patients taking this medication because patients frequently require dosage modifications, typically dose reductions,” Dr. Hill said in an interview. “Having this new program in which the medication has to be exchanged for a single-tablet dose makes it much more difficult and onerous to make those changes.”